# Roy Jones

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/roy-jones/

## Facts

| Field | Value |
| --- | --- |
| Citations | 16,603 |
| Field | Dementia and Cognitive Impairment Research |
| h-index | 64 |
| i10-index | 199 |
| Last Known Institution | The Research Institute for the Care of Older People |
| OpenAlex ID | https://openalex.org/A5048018080 |
| ORCID iD | 0000-0002-7953-5985 |
| Works | 407 |

## Researcher papers

- [Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial](https://scholariq.org/papers/long-term-effects-of-a-42-immunisation-in-alzheimer-s-disease-follow-up-of-a/)
- [Donepezil and Memantine for Moderate-to-Severe Alzheimer's Disease](https://scholariq.org/papers/donepezil-and-memantine-for-moderate-to-severe-alzheimer-s-disease/)
- [On the path to 2025: understanding the Alzheimer’s disease continuum](https://scholariq.org/papers/on-the-path-to-2025-understanding-the-alzheimer-s-disease-continuum/)
- [Coherent concepts are computed in the anterior temporal lobes](https://scholariq.org/papers/coherent-concepts-are-computed-in-the-anterior-temporal-lobes/)
- [Drug development in Alzheimer’s disease: the path to 2025](https://scholariq.org/papers/drug-development-in-alzheimer-s-disease-the-path-to-2025/)
- [Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease](https://scholariq.org/papers/randomized-controlled-trial-of-atorvastatin-in-mild-to-moderate-alzheimer/)
- [Memantine for patients with Parkinson's disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trial](https://scholariq.org/papers/memantine-for-patients-with-parkinson-s-disease-dementia-or-dementia-with-lewy/)
- [Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations](https://scholariq.org/papers/core-outcome-measures-for-interventions-to-prevent-or-slow-the-progress-of/)
- [Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British Association for Psychopharmacology](https://scholariq.org/papers/clinical-practice-with-anti-dementia-drugs-a-revised-third-consensus-statement/)
- [Evaluation of the safety and immunogenicity of synthetic Aβ42 (AN1792) in patients with AD](https://scholariq.org/papers/evaluation-of-the-safety-and-immunogenicity-of-synthetic-a-42-an1792-in-patients/)
- [Analysis of burden in caregivers of people with Alzheimer's disease using self-report and supervision hours](https://scholariq.org/papers/analysis-of-burden-in-caregivers-of-people-with-alzheimer-s-disease-using-self/)

## Researcher topics

- [Dementia and Cognitive Impairment Research](https://scholariq.org/topics/dementia-and-cognitive-impairment-research/)
- [Alzheimer's disease research and treatments](https://scholariq.org/topics/alzheimer-s-disease-research-and-treatments/)
- [Rural development and sustainability](https://scholariq.org/topics/rural-development-and-sustainability/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Cultural Heritage Management and Preservation](https://scholariq.org/topics/cultural-heritage-management-and-preservation/)

## Researcher university

- [The Research Institute for the Care of Older People](https://scholariq.org/institutions/the-research-institute-for-the-care-of-older-people/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.